SCHEMBL23419563

SCHEMBL23419563

CCOc1cc(-c2cccc3nc(CC(=O)Nc4ccc(Cl)nc4N)cn23)c(Cl)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MARS2 Q96GW9 4/20 0.46
▸ POLB P06746 3/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ MAPT P10636 5/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ TSHR P16473 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ MAPK8 P45983 2/20 0.33
▸ MAPK9 P45984 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ PPARG P37231 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.33
▸ NCOR2 Q9Y618 1/20 0.33
▸ ATR Q13535 1/20 0.33
▸ TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20596490 0.83 MARS2 (0.42) MARS2ALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL23419568 0.82 MARS2 (0.38) MARS2POLBMAPTLMNATP53
SCHEMBL23419199 0.77 MARS2 (0.41) MARS2POLBSMN1; SMN2MAPTMEN1
SCHEMBL23419558 0.73 MARS2 (0.47) MARS2POLBSMN1; SMN2MAPT
SCHEMBL20596076 0.73 NOD2 (0.38) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL20595823 0.72 MARS2 (0.84) MARS2POLBSMN1; SMN2MAPT
SCHEMBL20595835 0.70 MEN1 (0.38) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL20596598 0.69 F10 (0.43) MARS2POLBALDH1A1SMN1; SMN2MAPT
SCHEMBL23419542 0.69 CYP2C8 (0.36) —
SCHEMBL20596051 0.67 CA12 (0.37) POLBALDH1A1SMN1; SMN2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 MARS2 12/4885POLB 424/4885ALDH1A1 1461/4885
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR MARS2 5/4885POLB 459/4885ALDH1A1 2337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback